CN1562144A - Chinese medicinal composition for treating intestine irritable syndrome and its preparing method - Google Patents
Chinese medicinal composition for treating intestine irritable syndrome and its preparing method Download PDFInfo
- Publication number
- CN1562144A CN1562144A CN 200410014704 CN200410014704A CN1562144A CN 1562144 A CN1562144 A CN 1562144A CN 200410014704 CN200410014704 CN 200410014704 CN 200410014704 A CN200410014704 A CN 200410014704A CN 1562144 A CN1562144 A CN 1562144A
- Authority
- CN
- China
- Prior art keywords
- gram
- soft capsule
- rhizoma atractylodis
- atractylodis macrocephalae
- pericarpium citri
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 13
- 239000000203 mixture Substances 0.000 title claims description 45
- 210000000936 intestine Anatomy 0.000 title description 2
- 208000011580 syndromic disease Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 139
- 208000002551 irritable bowel syndrome Diseases 0.000 claims abstract description 30
- 239000007788 liquid Substances 0.000 claims abstract description 24
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 64
- 239000007901 soft capsule Substances 0.000 claims description 56
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
- 239000000341 volatile oil Substances 0.000 claims description 33
- 238000011282 treatment Methods 0.000 claims description 27
- 230000000694 effects Effects 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 23
- 239000000284 extract Substances 0.000 claims description 21
- 238000000108 ultra-filtration Methods 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 14
- 239000000047 product Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 229940057995 liquid paraffin Drugs 0.000 claims description 12
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 12
- 239000008158 vegetable oil Substances 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 239000000084 colloidal system Substances 0.000 claims description 9
- -1 filtered Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 8
- 238000000465 moulding Methods 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 7
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 6
- 238000009413 insulation Methods 0.000 claims description 6
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 238000000748 compression moulding Methods 0.000 claims description 3
- 238000010924 continuous production Methods 0.000 claims description 3
- 238000002481 ethanol extraction Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000000576 food coloring agent Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 239000003292 glue Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000010271 massa medicata fermentata Substances 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 238000001256 steam distillation Methods 0.000 claims description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 abstract description 6
- 239000003826 tablet Substances 0.000 abstract description 4
- 241000132012 Atractylodes Species 0.000 abstract 1
- 241000675108 Citrus tangerina Species 0.000 abstract 1
- 241000229179 Ledebouriella Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000010773 plant oil Substances 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 description 39
- 229940079593 drug Drugs 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 24
- 210000000952 spleen Anatomy 0.000 description 19
- 230000008485 antagonism Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 241000208340 Araliaceae Species 0.000 description 9
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 9
- 235000003140 Panax quinquefolius Nutrition 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 235000008434 ginseng Nutrition 0.000 description 9
- 206010012735 Diarrhoea Diseases 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000003871 intestinal function Effects 0.000 description 6
- 210000002460 smooth muscle Anatomy 0.000 description 6
- 206010000087 Abdominal pain upper Diseases 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229930003347 Atropine Natural products 0.000 description 4
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- 229960000396 atropine Drugs 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 229960002362 neostigmine Drugs 0.000 description 4
- ALWKGYPQUAPLQC-UHFFFAOYSA-N neostigmine Chemical compound CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 ALWKGYPQUAPLQC-UHFFFAOYSA-N 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 3
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 3
- 229910001626 barium chloride Inorganic materials 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 3
- 229960003147 reserpine Drugs 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 2
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000001671 psychotherapy Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000012913 prioritisation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910021647 smectite Inorganic materials 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 208000016303 spleen symptom Diseases 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410014704 CN1258372C (en) | 2004-04-20 | 2004-04-20 | Chinese medicinal composition for treating intestine irritable syndrome and its preparing method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410014704 CN1258372C (en) | 2004-04-20 | 2004-04-20 | Chinese medicinal composition for treating intestine irritable syndrome and its preparing method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1562144A true CN1562144A (en) | 2005-01-12 |
CN1258372C CN1258372C (en) | 2006-06-07 |
Family
ID=34478540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410014704 Expired - Lifetime CN1258372C (en) | 2004-04-20 | 2004-04-20 | Chinese medicinal composition for treating intestine irritable syndrome and its preparing method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1258372C (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102247459A (en) * | 2010-05-18 | 2011-11-23 | 南京中科药业有限公司 | Traditional Chinese medicine composite for treating gstrointestinal dysfunction and preparation method thereof |
CN101474275B (en) * | 2008-11-11 | 2012-01-25 | 深圳海王药业有限公司 | Preparation method and application of Chinese medicine extract for 'prescription for treating diarrhoea with abdominal pain' |
CN102397372A (en) * | 2011-11-17 | 2012-04-04 | 云南云药科技股份有限公司 | Medicinal composition and pharmaceutical preparation and application thereof to treating irritable bowel syndrome |
CN103127487A (en) * | 2013-03-19 | 2013-06-05 | 刘华荣 | Traditional Chinese medicine compound for treatment of diarrhea after brain surgery |
CN105012846A (en) * | 2015-08-10 | 2015-11-04 | 王艳娣 | Traditional Chinese medicine composition for treating infantile diarrhea |
CN105031604A (en) * | 2015-09-19 | 2015-11-11 | 庞群 | Irritable bowel syndrome and treating medicine thereof |
-
2004
- 2004-04-20 CN CN 200410014704 patent/CN1258372C/en not_active Expired - Lifetime
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101474275B (en) * | 2008-11-11 | 2012-01-25 | 深圳海王药业有限公司 | Preparation method and application of Chinese medicine extract for 'prescription for treating diarrhoea with abdominal pain' |
CN102247459A (en) * | 2010-05-18 | 2011-11-23 | 南京中科药业有限公司 | Traditional Chinese medicine composite for treating gstrointestinal dysfunction and preparation method thereof |
CN102247459B (en) * | 2010-05-18 | 2013-07-24 | 南京中科药业有限公司 | Traditional Chinese medicine composite for treating gstrointestinal dysfunction and preparation method thereof |
CN102397372A (en) * | 2011-11-17 | 2012-04-04 | 云南云药科技股份有限公司 | Medicinal composition and pharmaceutical preparation and application thereof to treating irritable bowel syndrome |
CN103127487A (en) * | 2013-03-19 | 2013-06-05 | 刘华荣 | Traditional Chinese medicine compound for treatment of diarrhea after brain surgery |
CN105012846A (en) * | 2015-08-10 | 2015-11-04 | 王艳娣 | Traditional Chinese medicine composition for treating infantile diarrhea |
CN105031604A (en) * | 2015-09-19 | 2015-11-11 | 庞群 | Irritable bowel syndrome and treating medicine thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1258372C (en) | 2006-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1211107C (en) | Mixture for improving blood circulation | |
CN100349598C (en) | Medicine for treating high lipemia and its production method | |
CN1663597A (en) | Qi-invigorating, blood-nourishing medicinal composition and its preparing method | |
CN1245198C (en) | Chinese medicine composition for treating diabetes and its preparing method | |
CN1239183C (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
CN101049324A (en) | Composition of medication prepared from ginkgo leaves and puerarin | |
CN1562144A (en) | Chinese medicinal composition for treating intestine irritable syndrome and its preparing method | |
CN1724060A (en) | A kind of pharmaceutical composition for the treatment of depression and preparation method thereof | |
CN1201805C (en) | Combination of medication for reducing poison and synergic action in radiotherapy or chemotherapy as well as its preparing method | |
CN100341492C (en) | Ginseng-astragalus blood-sugar lowering soft capsule, and its preparing and detecting method | |
CN1562337A (en) | Chinese traditional medicine for treating insufficiency of kidney-yang and preparaton method | |
CN1931233A (en) | Medicine composition of red sage and epimedium for treating cardiac and cerebral vascular diseases | |
CN1679901A (en) | Compound preparation of Jianganling for liver and its making method | |
CN1650996A (en) | Medicinal composition, its preparation method and application | |
CN1194743C (en) | Chinese medicinal composition for treating atrophic arthritis, preparing method and quality controlling method thereof | |
CN1565591A (en) | Preparation and usage of | |
CN101040934A (en) | Medicine compound made of haw leaf and rhodiola | |
CN101049355A (en) | Composition of medication prepared from safflower and leaves of hawthorn | |
CN1634302A (en) | Medicine for treating gout, hyperuricemia and hyperlipemia and preparation method thereof | |
CN1857609A (en) | Chinese medicine composition with nourishing health function and its preparing method | |
CN1634496A (en) | Chinese traditional medicine composition for treating diabetes and preparation method thereof | |
CN1579485A (en) | Traditional Chinese medicinal composition for treating intestinal function disorder and its preparation method | |
CN1626103A (en) | Combination of medication of containing general saponin of notoginseng and icariin as well as usage | |
CN1736429A (en) | Blood stasis dispelling dripping pills for treating coronary heart disease, angina pectoris and hyperlipemia and preparation process thereof | |
CN1726987A (en) | Combined of Chinese traditional medicine for lowering blood sugar, preparation and discrimination method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU KANGCHEN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: BIOLOGICAL ENGINEERING + MEDICINES TECH DEVELOPMENT CO., LTD., NANJING Effective date: 20050225 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050225 Address after: 510530, Guangzhou economic and Technological Development Zone, Eastern District Dongpeng Avenue No. 71 Applicant after: GUANGZHOU CONSUN PHARMACEUTICAL Co.,Ltd. Address before: 301 room 15, building 210032, hi tech Development Zone, Jiangsu, Nanjing Applicant before: NANJING B & M SCIENCE AND TECH |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: KANGYUAN PHARMACEUTICAL INDUSTRIAL CO LTD, INNER M Free format text: FORMER OWNER: KANGCHEN PHARMACEUTICAL CO., LTD., GUANGZHOU Effective date: 20121218 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: GUANGZHOU, GUANGDONG PROVINCE TO: 028100 TONGLIAO, INNER MONGOLIA AUTONOMOUS REGION |
|
TR01 | Transfer of patent right |
Effective date of registration: 20121218 Address after: 028100 Inner Mongolia Tongliao kezuohouqi Ganqika Tiedong Patentee after: KANGYUAN PHARMACEUTICAL INDUSTRIAL Co.,Ltd. INNER MONGOLIA Address before: Guangzhou economic and Technological Development Zone, Eastern District Dongpeng Avenue No. 71 Patentee before: GUANGZHOU CONSUN PHARMACEUTICAL Co.,Ltd. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151225 Address after: 028100 the Inner Mongolia Autonomous Region Tongliao kezuohouqi Ganqika Industrial Park No. 2 North Road Patentee after: Kangchen Pharmaceutical (Inner Mongolia) Co.,Ltd. Address before: 028100 the Inner Mongolia Autonomous Region Tongliao kezuohouqi Ganqika Tiedong Patentee before: KANGYUAN PHARMACEUTICAL INDUSTRIAL Co.,Ltd. INNER MONGOLIA |
|
CX01 | Expiry of patent term |
Granted publication date: 20060607 |
|
CX01 | Expiry of patent term |